On October 11, 2017 Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled “Beyond PARP – Next Generation DDR Therapeutics” at the 2017 BIO Investor Forum in San Francisco (Press release, Sierra Oncology, OCT 11, 2017, View Source [SID1234520850]).

The presentation is scheduled for 11:00 am PT on Tuesday, October 17th. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com.